Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia

The role of cefepime for extended-spectrum β-lactamase (ESBL) bacteremia is unclear if susceptible in vitro. In a propensity score-matched study of patients with ESBL bacteremia, risk of death was 2.87 times higher for patients receiving cefepime compared with carbapenems (95% confidence interval [C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruibin, Cosgrove, Sara E., Tschudin-Sutter, Sarah, Han, Jennifer H., Turnbull, Alison E., Hsu, Alice J., Avdic, Edina, Carroll, Karen C., Tamma, Pranita D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942761/
https://www.ncbi.nlm.nih.gov/pubmed/27419191
http://dx.doi.org/10.1093/ofid/ofw132
_version_ 1782442474859397120
author Wang, Ruibin
Cosgrove, Sara E.
Tschudin-Sutter, Sarah
Han, Jennifer H.
Turnbull, Alison E.
Hsu, Alice J.
Avdic, Edina
Carroll, Karen C.
Tamma, Pranita D.
author_facet Wang, Ruibin
Cosgrove, Sara E.
Tschudin-Sutter, Sarah
Han, Jennifer H.
Turnbull, Alison E.
Hsu, Alice J.
Avdic, Edina
Carroll, Karen C.
Tamma, Pranita D.
author_sort Wang, Ruibin
collection PubMed
description The role of cefepime for extended-spectrum β-lactamase (ESBL) bacteremia is unclear if susceptible in vitro. In a propensity score-matched study of patients with ESBL bacteremia, risk of death was 2.87 times higher for patients receiving cefepime compared with carbapenems (95% confidence interval [CI], .88–9.41). We compared 14-day mortality of patients with ESBL bacteremia receiving empiric cefepime versus empiric carbapenem therapy in a propensity score-matched cohort. There was a trend towards increased mortality in the cefepime group (hazard ratio, 2.87; 95% CI, .88–9.41), which enhances the existing literature suggesting that cefepime may be suboptimal for invasive ESBL infections.
format Online
Article
Text
id pubmed-4942761
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-49427612016-07-14 Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia Wang, Ruibin Cosgrove, Sara E. Tschudin-Sutter, Sarah Han, Jennifer H. Turnbull, Alison E. Hsu, Alice J. Avdic, Edina Carroll, Karen C. Tamma, Pranita D. Open Forum Infect Dis Brief Reports The role of cefepime for extended-spectrum β-lactamase (ESBL) bacteremia is unclear if susceptible in vitro. In a propensity score-matched study of patients with ESBL bacteremia, risk of death was 2.87 times higher for patients receiving cefepime compared with carbapenems (95% confidence interval [CI], .88–9.41). We compared 14-day mortality of patients with ESBL bacteremia receiving empiric cefepime versus empiric carbapenem therapy in a propensity score-matched cohort. There was a trend towards increased mortality in the cefepime group (hazard ratio, 2.87; 95% CI, .88–9.41), which enhances the existing literature suggesting that cefepime may be suboptimal for invasive ESBL infections. Oxford University Press 2016-06-20 /pmc/articles/PMC4942761/ /pubmed/27419191 http://dx.doi.org/10.1093/ofid/ofw132 Text en © The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Brief Reports
Wang, Ruibin
Cosgrove, Sara E.
Tschudin-Sutter, Sarah
Han, Jennifer H.
Turnbull, Alison E.
Hsu, Alice J.
Avdic, Edina
Carroll, Karen C.
Tamma, Pranita D.
Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
title Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
title_full Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
title_fullStr Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
title_full_unstemmed Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
title_short Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
title_sort cefepime therapy for cefepime-susceptible extended-spectrum β-lactamase-producing enterobacteriaceae bacteremia
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942761/
https://www.ncbi.nlm.nih.gov/pubmed/27419191
http://dx.doi.org/10.1093/ofid/ofw132
work_keys_str_mv AT wangruibin cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT cosgrovesarae cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT tschudinsuttersarah cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT hanjenniferh cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT turnbullalisone cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT hsualicej cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT avdicedina cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT carrollkarenc cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia
AT tammapranitad cefepimetherapyforcefepimesusceptibleextendedspectrumblactamaseproducingenterobacteriaceaebacteremia

Ejemplares similares